Systemic Inflammatory Response Syndrome Treatment Market Size To Hit USD 24.76 Bn By 2034

The Systemic Inflammatory Response Syndrome Treatment Market is witnessing significant growth, with its market size expected to reach USD 24.76 billion by 2034, up from USD 13.85 billion in 2024. This represents a compound annual growth rate (CAGR) of 5.98% over the forecast period from 2024 to 2034.

Table of Contents

Market Overview

The SIRS treatment market is experiencing steady growth due to the increasing global burden of infectious diseases, trauma, and critical illnesses. Systemic inflammatory response syndrome arises as a critical response to infections, burns, pancreatitis, or trauma, potentially leading to severe inflammation, multi-organ failure, and sepsis if untreated. The market benefits from innovations in early diagnosis, anti-inflammatory therapies, and supportive ICU care.

The aging global population, which is more vulnerable to immune-related complications, is also driving demand for SIRS treatment options. Additionally, pharmaceutical advancements, such as biologics, immunomodulatory therapies, and targeted drug delivery systems, are improving treatment outcomes and encouraging market expansion.

Key Market Insights

Market Size in 2024: USD 13.85 billion
Market Size by 2034: USD 24.76 billion
CAGR (2025 to 2034): 5.98%
North America: The largest regional market, capturing 38.89% of the revenue share in 2024.
Hospital & Ambulatory Surgical Centers: The leading application segment, holding 62.15% of the revenue share in 2024.
Autoimmune Diseases: The product segment with 18.31% of the revenue share in 2024, contributing significantly to SIRS treatment.
Others: This category, including corticosteroids and immunomodulatory drugs, holds the largest share in the market with 53.41% of revenue in 2024.

Regional Analysis

North America: In 2024, North America captured the largest share of the market (38.89%), primarily driven by the U.S. healthcare system, which leads in terms of advanced diagnostic tools, treatment protocols, and research in critical care. The demand for rapid-response therapies, such as corticosteroids, immunomodulators, and biologics, is strong, with a high incidence of sepsis and critical care admissions.
Asia Pacific: The region is expected to witness the fastest growth rate during the forecast period. China is emerging as a key player due to government-led healthcare reforms, hospital readiness improvements, and growing public awareness. Additionally, India and Japan are seeing an increase in domestic biotech innovations catering to local demand.
Europe: Although Europe lags behind North America in market share, it remains a strategic market with countries like Germany, France, and the UK showing robust infrastructure and high clinical awareness. Reimbursement regimes for SIRS treatments and a high standard of clinical practice further contribute to market growth.

Growth Factors

Increased Prevalence of Inflammatory and Infectious Diseases: The rising burden of conditions like sepsis, acute pancreatitis, and infections is fueling demand for SIRS treatments. The increase in hospital-acquired infections and antibiotic resistance are adding urgency to the need for effective therapies.
Improved Diagnostic and Monitoring Technologies: Real-time patient monitoring, biomarker recognition, and early screening technologies are improving the speed of diagnosis and treatment of SIRS, directly enhancing treatment outcomes.
Aging Population: The growing elderly population, with its higher risk of immune-related complications, is significantly contributing to the demand for SIRS therapies. Older individuals are more vulnerable to systemic inflammation, which results in higher treatment requirements.
Innovative Drug Delivery Systems: Advances in nanotechnology and controlled-release drug delivery systems are improving the effectiveness of SIRS treatments while minimizing systemic side effects.
Targeted Immunotherapies: Research and development in immunomodulatory medications, monoclonal antibodies, and biologics are enabling more personalized treatment options, providing tailored therapies based on the individual’s immune profile.

Market Challenges

Antibiotic Resistance: One significant challenge to treating SIRS is the growing problem of antibiotic resistance, which complicates the treatment of infections that lead to SIRS. This necessitates the development of novel treatment strategies, including immunomodulators and biologics.

Opportunities

Innovative Drug Delivery Systems: The development of advanced drug delivery systems, such as nanoparticles and controlled release formulations, presents an opportunity to improve the precision of SIRS treatment and reduce systemic side effects.
Personalized Medicine: Utilizing biomarkers for personalized treatment based on genetic and immunological profiles is a significant growth opportunity in SIRS management.

Product Insights

Others Segment: In 2024, the Others segment dominated the market with 53.41% revenue share. This includes treatments like corticosteroids, NSAIDs, and immunomodulatory compounds that are vital for reducing inflammation in critical SIRS cases.
Urinary Tract Infection (UTI): This product segment is important in the SIRS treatment market due to its contribution to the syndrome’s progression. Effective UTI management is crucial in preventing further inflammatory damage and complications.

Mode of Administration Insights

Injectable Segment: The injectable segment holds the largest market share due to its convenience and efficacy in critical care settings. Intravenous corticosteroids, immunomodulators, and biologics are commonly administered through injectables for quick therapeutic action.
Oral Segment: The oral segment is the fastest-growing, as oral anti-inflammatories and immunosuppressives offer a more convenient and non-invasive treatment option for post-acute care and long-term management.

Application Insights

Hospital & Ambulatory Surgical Centers: This segment dominates the SIRS treatment market, capturing the largest market share due to the advanced infrastructure, ICU capabilities, and specialized medical professionals involved in critical care.
Specialty Clinics: Specialty clinics, focusing on advanced inflammation treatments and therapies, are the fastest-growing segment, providing a more targeted and disease-specific treatment approach for non-emergent SIRS cases.

Recent Developments

CytoSorbents launched the PuriFi™ hemoperfusion pump in June 2024, which accelerates cytokine adsorption therapy for severe SIRS cases, especially in the ICU and cardiac suites.
CytoSorbents also secured regulatory certifications and international orders for their PuriFi and DrugSorb-ATR devices, enhancing their position in the market.

Key Players in the Market

GlaxoSmithKline
AstraZeneca
CytoSorbents Corporation
Cardinal Health
Asahi Kasei
ConvaTec
CHIESI Farmaceutici
Smith & Nephew

For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com

About
Latest Posts

ritika jankar